Oral nonsteroidal anti-inflammatory drugs for neuropathic pain

Not all studies reported all the outcomes of interest. Analyses consistently showed no significant difference between NSAID and placebo : substantial benefit (at least 50% pain intensity reduction) ( risk difference ( RD ) - (95% confidence interval ( CI ) - to ) 2 studies, 146 participants; moderate benefit (at least 30% pain intensity reduction) ( RD - (95% CI - to ) 3 studies, 192 participants; withdrawals due to adverse events ( RD (95% CI - to ) 4 studies, 230 participants; participants experiencing any adverse event ( RD (95% CI - to ) 4 studies, 230 participants; all-cause withdrawals ( RD (95% CI - to ) 3 studies, 192 participants. There were no serious adverse events or deaths. Although most studies had some measures of health-related quality of life, fibromyalgia impact, or other outcomes, none reported the outcomes beyond saying that there was no or little difference between the treatment groups.

Oral nonsteroidal anti-inflammatory drugs for neuropathic pain

oral nonsteroidal anti-inflammatory drugs for neuropathic pain

Media:

oral nonsteroidal anti-inflammatory drugs for neuropathic painoral nonsteroidal anti-inflammatory drugs for neuropathic painoral nonsteroidal anti-inflammatory drugs for neuropathic painoral nonsteroidal anti-inflammatory drugs for neuropathic painoral nonsteroidal anti-inflammatory drugs for neuropathic pain

http://buy-steroids.org